Document is current
Any future updates will be listed below
-
Authors
Zhou, Sining
Liu, Yiming
Zhang, Qi
Xu, Huikang
Fang, Yangxin
Chen, Xin
Fu, Jiamin
Yuan, Yin
Li, Yifei
Yuan, Li
Xiang, Charlie https://orcid.org/0000-0002-9193-3900
-
Funding
Funding for this research was provided by:
Zhejiang Key Research and Development Program (2019C03015, 2020C03125)
National Science and Technology Major Project (2018ZX09201002-005)
National Key R&D Program of China (2017YFA0105701)
CAMS Innovation Fund for Medical Sciences (2019-I2M-5-045)
- License Information
-
More Information
Article History
Received: 10 August 2022
Accepted: 13 March 2023
First Online: 1 April 2023
Declarations
:
: All of our animal experiments were approved by the Laboratory Animal Welfare and Ethics Committee of Zhejiang University on Nov. 21, 2021. The ethics code is ZJU20210278. The project title is "MenSCs reverse sorafenib resistance in hepatocellular carcinoma cells in a hypoxic microenvironment."
: Not applicable.
: The authors have declared that no competing interest exists.
